{"id":"mencevaxacwy","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site pain"},{"rate":"10-20","effect":"Injection site erythema"},{"rate":"10-20","effect":"Injection site swelling"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsular antigens from meningococcal serogroups A, C, W, and Y conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune responses. Upon administration, it primes both humoral and cellular immunity to recognize and neutralize these meningococcal strains, providing protection against invasive meningococcal disease caused by these serogroups.","oneSentence":"Mencevax ACWY is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:42.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT00514904","phase":"PHASE3","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-18","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":1504},{"nctId":"NCT00661557","phase":"PHASE2","title":"Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-19","conditions":"Infections, Meningococcal","enrollment":271},{"nctId":"NCT01154088","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-27","conditions":"Infections, Meningococcal","enrollment":1170},{"nctId":"NCT00453986","phase":"PHASE3","title":"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-09","conditions":"Infections, Meningococcal","enrollment":1352},{"nctId":"NCT00356369","phase":"PHASE2","title":"Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-23","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT00464815","phase":"PHASE3","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-02","conditions":"Infections, Meningococcal","enrollment":1025},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT00291343","phase":"PHASE3","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-01","conditions":"Infections, Meningococcal","enrollment":296},{"nctId":"NCT00427908","phase":"PHASE2","title":"Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-07","conditions":"Infections, Meningococcal","enrollment":613},{"nctId":"NCT00390143","phase":"PHASE2","title":"Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Infections, Meningococcal","enrollment":46},{"nctId":"NCT00126984","phase":"PHASE2","title":"Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"Infections, Meningococcal","enrollment":508},{"nctId":"NCT00227422","phase":"PHASE4","title":"Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06","conditions":"Infections, Meningococcal","enrollment":324},{"nctId":"NCT00126945","phase":"PHASE2","title":"Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":"Infections, Meningococcal","enrollment":125},{"nctId":"NCT00196963","phase":"PHASE2","title":"Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Infections, Meningococcal","enrollment":125},{"nctId":"NCT00196950","phase":"PHASE2","title":"Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Infections, Meningococcal","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mencevax™ACWY","genericName":"Mencevax™ACWY","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mencevax ACWY is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}